[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340018-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-340018-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","pyrimidine-triones-as-potential-activators-of-p53-mutants-article","Pyrimidine Triones as Potential Activators of p53 Mutants - Article","","p53 is a crucial tumor suppressor in vertebrates, frequently mutated in human cancers, where many missense variants lose anti-tumor function. Small-molecule strategies aim to convert mutant p53 into an active, wild-type-like conformation, potentially enabling personalized cancer therapy. This study evaluates the UCI-1001 compound series as a candidate p53 corrector for multiple p53 mutations, showing growth inhibition and restored p53 functions. Assays including cellular thermal shift, conformation-specific immunofluorescence, and DSF support UCI-1001-induced conformational remodeling in mutant cancer cells.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pyrimidine-triones-as-potential-activators-of-p53-mutants-article/340018/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pyrimidine-triones-as-potential-activators-of-p53-mutants-article/340018.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What experimental methods support the proposed mechanism?","Question",{"text":63,"@type":64},"Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry indicate that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},340018,1790664110,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":91,"preview_page_count":33,"preview_urls":137},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","biomolecules  \nArticle  \nPyrimidine Triones as Potential Activators of p53 Mutants  \nMaryam M. Jebril Fallatah 1, Özlem Demir2,†, Fiona Law 1, Linda Lauinger 1, Roberta Baronio 1,‡, Linda Hall 1, Elodie Bournique 1, Ambuj Srivastava 2, Landon Tyler Metzen 1, Zane Norman 1,§ , Rémi Buisson 1, Rommie E. Amaro 2,* and Peter Kaiser 1, *  \nCitation: Fallatah, M.M.J.; Demir, Ö.; Law, F.; Lauinger, L.; Baronio, R.; Hall, L.; Bournique, E.; Srivastava, A.; Metzen, L.T.; Norman, Z.; et al. Pyrimidine Triones as Potential Activators of p53 Mutants.  \nBiomolecules 2024, 14, 967 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biom14080967  \nAcademic Editor: Leonard B.  \nMaggi Jr.  \nReceived: 29 April 2024  \nRevised: 22 July 2024  \nAccepted: 5 August 2024  \nPublished: 8 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Biological Chemistry, University of California Irvine, Irvine, CA 92697, USA  \n2 Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA  \n* Correspondence: [ramaro@ucsd.edu](ramaro@ucsd.edu) (R.E.A.); [pkaiser@uci.edu](pkaiser@uci.edu) (P.K.); Tel.: +1-858-534-9629 (R.E.A.);+1-949-824-9367 (P.K.)  \n† Current address: Novartis Biomedical Research, San Diego, CA 92121, USA.  \n‡ Current address: Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ, UK.  \n§ Current address: Sapient Bioanalytics, San Diego, CA 92121, USA.  \nAbstract: p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.  \nKeywords: mutant p53; tumor suppressor; CETSA; DSF; p53 corrector; p53 reactivator; cancer  \n1. Introduction  \nThe p53 protein, encoded by the TP53 gene, serves as a vital tumor suppressor invertebrates, playing a crucial role in preventing the initiation and progression of cancer. However, most tumors have developed strategies to counteract the anti-cancer functions of p53, making the p53 pathway an attractive target for pharmaceutical cancer therapies. p53, which is present in both the nucleus and cytoplasm, acts as a transcription factor, selectively binding to DNA and governing the expression of various genes [1,2] . Under regular circumstances, the levels of cellular p53 protein remain minimal due to stringent regulation by its inhibitors Mdm2 and MdmX. These inhibitors facilitate the degradation of p53 vi","cbCaioJZ7PGt5kuY","https://ap.wps.com/l/cbCaioJZ7PGt5kuY","pdf",34817053,24,"English","# Introduction\n## p53 as a tumor suppressor and regulation\n## p53 mutations and hotspot classifications\n## Rationale for small-molecule p53 reactivation\n# Study scope and compound series\n## UCI-1001 as a potential p53 corrector\n## Cellular readouts and mechanistic assays","[{\"question\":\"What experimental methods support the proposed mechanism?\",\"answer\":\"Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry indicate that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells.\"}]","Pyrimidine Triones as Potential Activators of p53 Mutants - Article | PDF",1790033759,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b80e502ad80878c68ccf38d8912b5fd5.webp",983,1390,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3a803784ac02f2dc2b8a6ebb4dc98b.webp",982,1388,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/771b5d161c2d1db409b76e895655c913.webp",981,1387,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/563506e266b6efc7de2ce4fb087ed2de.webp",980,1385]